3 results
Primary Objectives:* To compare overall survival (OS) of patients who receive NKTR-102given once every 21 days (q21d) to patients who receive Treatment ofPhysician*s Choice (TPC) selected from the following list of seven singleagentintravenous…
Primary:To compare the efficacy of abrocitinib 200 mg once daily (QD) versus dupilumab (as per label guidelines) in adult participants on background topical therapy with moderate to severe atopic dermatitis (AD).Key SecondaryTo compare the efficacy…
Primary Objective: To evaluate the *Triple Aim* performance of Care Pathway Technology for RA: - Evaluate and compare predefined RA health outcomes; Disease activity measured by DAS 28 joint score at baseline, month 12; RAPID3, HAQ-DI at baseline…